Adagene posts US$127.9M cash as of June 30, 2026

Adagene Inc., a biotechnology company listed as a foreign private issuer, reported that it held US$127.9 million in unaudited cash and cash equivalents as of June 30, 2026.

Rhea-AI Filing Summary

Adagene Inc., a biotechnology company listed as a foreign private issuer, reported that it held US$127.9 million in unaudited cash and cash equivalents as of June 30, 2026. This figure is described as preliminary, unaudited and subject to finalization.

The company emphasized that this cash information is not a substitute for full audited financial statements prepared under US GAAP and is not incorporated by reference into its other U.S. SEC filings. The update simply provides investors with an early view of Adagene’s liquidity position.

Key Figures

Cash and cash equivalents: US$127.9 million

1 metrics

Cash and cash equivalents US$127.9 million Unaudited, as of June 30, 2026

Key Terms

foreign private issuer, unaudited, US GAAP

3 terms

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

unaudited financial

"had unaudited cash and cash equivalents of US$127.9 million"

"Unaudited" describes financial statements or reports that have not been examined or verified by an independent accountant or auditor. Because they haven't undergone this review, they may not be as reliable or accurate as audited reports, making them less certain for investors to rely on when assessing a company's financial health. Think of it as a preliminary estimate that could change once checked by an expert.

US GAAP financial

"audited financial statements prepared in accordance with US GAAP"

U.S. GAAP is the set of official accounting rules and standards companies in the United States use to record and report their financial results. Like a common recipe book for financial statements, it makes company reports consistent and easier to compare, so investors can better judge profitability, risk and trends when deciding to buy, hold or sell shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cash balance did Adagene (ADAG) report as of June 30, 2026?

Adagene reported holding US$127.9 million in cash and cash equivalents as of June 30, 2026. This figure is preliminary, unaudited, subject to finalization, and meant as an early indication of the company’s liquidity rather than a full financial statement.

Is Adagene’s June 30, 2026 cash figure audited?

No, the US$127.9 million cash and cash equivalents figure is unaudited and preliminary. Adagene notes it remains subject to finalization and should not be treated as a replacement for full audited financial statements prepared in accordance with US GAAP standards.

Does the Adagene (ADAG) cash disclosure replace its US GAAP financial statements?

No, Adagene explicitly states this cash disclosure does not replace audited US GAAP financial statements. It is a limited liquidity snapshot and should be considered alongside complete financial reports once they are issued and audited under applicable accounting standards.

Is Adagene’s June 2026 cash disclosure incorporated into other SEC filings?

Adagene clarifies that the US$127.9 million cash figure is not incorporated by reference into any of its other U.S. SEC filings. It stands alone as a preliminary liquidity update on Form 6-K, separate from previously filed or future reports.

What SEC reporting framework does Adagene (ADAG) use for annual reports?

Adagene files its annual reports under Form 20-F as a foreign private issuer. This 6-K cash update complements, but does not alter or replace, the more comprehensive disclosures that will appear in its periodic Form 20-F filings with the SEC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 08:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-

16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2026

Commission File Number: 001-39997

Adagene Inc.

4F, Building C14, No. 218

Xinghu Street, Suzhou Industrial Park

Suzhou, Jiangsu Province, 215123

People’s Republic of China

+86-512-8777-3632

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x     Form 40-F ¨

As of June 30, 2026, Adagene Inc. (the “Company”) had unaudited cash and cash equivalents of US$127.9 million. Such amount of cash and cash equivalents is preliminary, unaudited and subject to finalization. This financial information should not be viewed as a substitute for the audited financial statements prepared in accordance with US GAAP, and is not incorporated by reference into any of the Company’s filings with the U.S. Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Adagene Inc.
	By:	/s/ Peter Luo
	Name:	Peter Luo
	Title:	Chief Executive Officer

Date: July 6, 2026